{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:16Z","timestamp":1787841316057,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"vor","delay-in-days":231,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:sec>\n                    <jats:title>INTRODUCTION:<\/jats:title>\n                    <jats:p>This practice survey is conducted to analyze clinical hematopoietic stem cell transplantation (HSCT) practice variability among centers in the WHO Eastern Mediterranean Region (EMRO), as represented by the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHOD:<\/jats:title>\n                    <jats:p>Th is internet based survey was completed by the medical program directors of the EMBMT centers; 17 centers participated. The survey collected data on various clinical aspects of HSCT practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Consistency in pre HSCT cardiac (100%), pulmonary (82%) and viral screen (100%) was observed. Obtaining informed consent was universal. Pre-HSCT psychological assessment is practiced in 50% of the centers. All centers used single-bedded rooms with HEPA filters. Visitor policy during neutropenic phase and the use of gowns, masks or gloves when examining patients varied among centers. MRSA\/VRE screen and use of low bacterial diet were applied in 65% and 82%, respectively. Anti-bacterial prophylaxis is employed in 58% (Auto-SCT) and 60% (Allo-SCT) of the centers. Drug choice varied (cotrimoxazole, ciprofloxacin, levoflox-acin, piperacillin-tazobactam); 60% of the centers used penicillin prophylaxis in GVHD patients. PCP prophylaxis is applied in 58% (Auto-SCT) and 87% (Allo-SCT) of the centers; cotrimoxazole is usually used. Anti-viral prophylaxis with acyclovir or, less commonly, valacyclovir is used in 70% (Auto-SCT) and 93% (Allo-SCT) of centers. Anti-fungal prophylaxis is applied in 70% (Auto-SCT), 93% (myeloablative Allo-SCT) and 87% (reduced intensity [RIC] Allo-SCT). Fluconazole is used in all Auto-SCT and majority of Allo-SCT recipients; few centers used other agents (itraconazole, voriconazole, amphotericin B) in Allo-SCT. Prophylactic GCSF use varied among centers: Auto-SCT 77%, myeloablative Allo-SCT 33%, RIC Allo-SCT 27%. Use of ursodeoxycholic acid for venoocclusive disease (VOD) prophylaxis is variable: 60% (Allo-SCT) and 12% (Auto-SCT). Cyclosporine\/ methotrexate is the most commonly used GVHD prophylaxis in myeloablative Allo-SCT (93%); heterogeneity was seen in RIC SCT. Treatment of steroid refractory acute GVHD varied (ATG 53%, higher steroid dose 40%). CMV monitoring varied between antigenemia (53%) and PCR (40%) techniques. Pre-emptive anti CMV therapy is used in 86% of the centers, while 7% used routine CMV prophylaxis; 7% had no specific CMV management policy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Consistency was observed in areas of pre-SCT work up, use of single rooms, HEPA filters and GVHD prophylaxis. Heterogeneity is observed in other practice aspects including other isolation measures, antimicrobial prophylaxis, VOD prophylaxis, growth factor use and treatment of steroid refractory GVHD. Further studies are needed to probe the impact of such practice variations on post-transplant outcome and to ascertain the best clinical practice approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2013.04.001","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T15:10:11Z","timestamp":1366211411000},"page":"14-19","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO)"],"prefix":"10.4103","volume":"6","author":[{"given":"Walid","family":"Rasheed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir","family":"Ghavamzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemarie","family":"Hamladji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Ben Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Alseraihy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawzi","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Elhaddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"Alabdulaaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Amine","family":"Bekadja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Yousuf Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Naseem Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvez","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Benchekroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mani","family":"Ramzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Jarrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Alimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazal","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Hamidieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2013.04.001_b0005","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer, update by the infectious diseases society of america","volume":"52","author":"Freifeld","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.hemonc.2013.04.001_b0010","doi-asserted-by":"crossref","unstructured":"Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20142009 update. Bone Marrow Transplant; 46: 709\u201318.","DOI":"10.1038\/bmt.2010.175"},{"key":"10.1016\/j.hemonc.2013.04.001_b0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bmt.2009.254","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface","volume":"44","author":"Tomblyn","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2013.04.001_b0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.bbmt.2008.08.008","article-title":"Variation in supportive care practices in hematopoietic cell transplantation","volume":"14","author":"Lee","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2013.04.001_b0025","doi-asserted-by":"crossref","unstructured":"Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant; 17: 1528\u201336.","DOI":"10.1016\/j.bbmt.2011.03.006"},{"key":"10.1016\/j.hemonc.2013.04.001_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.bmt.1704727","article-title":"Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"35","author":"Ruutu","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2013.04.001_b0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/sj.bmt.1704423","article-title":"Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice","volume":"33","author":"Trifilio","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2013.04.001_b0040","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2007.15.0169","article-title":"Individual physician practice variation in hematopoietic cell transplantation","volume":"26","author":"Lee","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2013.04.001_b0045","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1182\/blood-2003-07-2430","article-title":"Physicians\u2019 attitudes about quality-of-life issues in hematopoietic stem cell transplantation","volume":"104","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2013.04.001_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bmt.2008.389","article-title":"Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report","volume":"43","author":"Aljurf","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2013.04.001_b0055","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2013.04.001_b0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/pon.1261","article-title":"Pre-transplant depression as risk factor for survival of patients undergoing allogeneic haematopoietic stem cell transplantation","volume":"17","author":"Grulke","year":"2008","journal-title":"Psychooncology"},{"key":"10.1016\/j.hemonc.2013.04.001_b0065","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2002.08.757","article-title":"Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases","volume":"20","author":"Loberiza","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2013.04.001_b0070","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2013.04.001_b0075","doi-asserted-by":"crossref","first-page":"975","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002","article-title":"Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Essell","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hemonc.2013.04.001_b0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N","article-title":"The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation","volume":"64","author":"Ohashi","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2013.04.001_b0085","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Tay","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2013.04.001_b0090","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1182\/blood-2008-10-143560","article-title":"How we treat cytomegalovirus in hematopoietic cell transplant recipients","volume":"113","author":"Boeckh","year":"2009","journal-title":"Blood"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387613000125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387613000125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201306010-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:37Z","timestamp":1787838577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201306010-00004"}},"subtitle":["Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey"],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2013.04.001","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}